•  
  •  
  •  
  •  

2026-08-04 12:08:27

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  Phase3

Stock Report

  • HFCL secures Contract of ~INR 2666.09 Crores from Rail Vikas Nigam Limited
  • Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer's Dementia
  • Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate
  • CuraTeQ Biologics announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11
  • Tejas Networks completes delivery of 17,000 IP/MPLS routers for BharatNet Phase III
  • Sumeet Industries announces ₹23.47 Cr Acquisition to Strengthen Polyester Chips Capacity
  • Phase III Clinical Trial of DengiAll® by ICMR and Panacea Biotec - Completion of enrollment of study participants
  • Tejas Networks emerges as a leading supplier of IP Routing products across the country for BharatNet Phase III packages
  • Brigade Enterprises Ltd acquires 4.04 acres in Neopolis Phase 3 Auction
  • THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • Sun Pharma's Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg in Active Psoriatic Arthritis Meet their Primary Endpoint
  • HFCL Ltd bags order aggregating to ~INR 157 Crores from Tera Software Ltd
  • ITI Limited initiates State Network Operations Center for BharatNet Phase-III Project in Himachal Pradesh
  • Birla Estates secures landmark booking value of approx INR 500cr for 3rd consecutive time with Phase 3 of Birla Trimaya in Bengaluru
  • Indian Regulatory Authority - SEC approval for conducting Phase III Clinical trials for Recombinant Human Albumin (rHA) 20%
  • Shilpa Medicare announces successful outcome of Phase 3 studies of SMLNUD07 - NorUDCA
  • Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024
  • Brigade Enterprises Ltd launches Brigade Oasis Phase-3
  • Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
  • Nidlegy™ Phase III PIVOTAL trial meets the study's primary objective
  • CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product
  • Suven Life Sciences announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine
  • Shilpa Medicare completes Human Clinical Studies of High Concentration Biosimilar Adalimumab

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025